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Abstract
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to
improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk
patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the
current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from
NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-
genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free
survival (PFS) and overall survival (OS) (cumulative R2= 18.4% and 25.2%, respectively). Integrating DNA drivers and
clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of
34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53
inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III,
comprising 6.1% of the population (median PFS= 15.4 months; OS= 20.7 months) that was validated in an independent
dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic
approaches.
Introduction
We have made consistent therapeutic progress for patients
with newly diagnosed multiple myeloma (NDMM) over the
last two decades; however, not all patients, especially high-
risk patients, have uniformly derived the benefit [1–12].
Patients with high-risk disease are associated with a poor
prognosis, but identifying these patients at diagnosis remain
a challenge. Multiple definitions of high-risk have evolved
over time, but today no definition is uniformly accepted or
implemented in clinical practice. Current approaches rely
upon cytogenetic and clinical biomarkers to define high-
risk, including the International Staging System (ISS) group
III, the presence of adverse translocations, and 17p deletion
(del17p); [3, 13, 14] however, non-uniform application and
interpretation of these variables have resulted in the
description of different high-risk groups with varying out-
comes. For example, the high-risk group identified by the
ISS is 33.6% with a median overall survival (OS) of
29 months, while the International Myeloma Working
Group (IMWG) identified a high-risk group of 20% with a
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4-year progression free survival (PFS) of 12% and OS of
35% [3, 13]. The revised ISS (R-ISS) is the most recent risk
stratification approach and incorporates the genetic markers
t(4;14) and del17p, but not 1q gain or mutational data from
TP53 as the data were not available [14]. The high-risk
group in the R-ISS classification comprised 10% and had a
median PFS of 29 months and 5-year OS of 40%. Thus,
although high-risk groups can be identified, the definition of
these groups and the specificity for very poor outcome
varies, confounding effective clinical decision making and
the design of risk-adjusted trials.
DNA drivers of biological activity are key determinants
of cancer behavior, are robust, and easily measured in the
clinical laboratory. While a number of mutational markers
have been identified [5, 15] as being associated with
prognosis, there has been no comprehensive approach to
integrate such markers into risk stratification approaches
because of small study size, use of focused disease panels,
and lack of follow-up, all of which can confound inter-
pretation of the results [2, 5, 15, 16]. As part of the Mye-
loma Genome Project (MGP), we have established the
largest repository of uniformly called molecular data asso-
ciated with clinical outcomes in NDMM, providing ade-
quate power to identify the variables associated with very
high-risk groups. Next-generation sequencing (NGS) data
was analyzed to comprehensively provide genome-wide
information on structural, mutational, and copy number
(CN) drivers, which can provide a global view of associa-
tion with outcome. We focused the analysis on the key
clinical problem of identifying high-risk patients destined
for early relapse and death, where a change in treatment
strategy could result in improved outcome.
The analysis identified a previously undescribed high-
risk segment that is defined by two DNA-based genomic
markers and key clinical data, that we refer to as Double-Hit
MM. Double-Hit patients have extremely poor prognosis,
even compared to other definitions of high risk. We propose
that future baseline risk assessments should include
screening for these patients to provide opportunities for
risk-adjusted therapy.
Materials and methods
Patient characteristics and statistical analysis
MGP is an ongoing collaborative research initiative to
assemble and uniformly analyze genetic datasets that have
been generated on samples obtained from patients with
NDMM (n= 1273). The project has collected multilevel
genetic data, giving it the power to identify the full spec-
trum of molecular drivers. The data has been assembled
from multiple groups across Europe and the USA, and has
undergone extensive quality control.
NGS data were processed and analyzed uniformly,
Supplementary Methods, Supplementary Figure 3, Supple-
mentary Table 1, and associated genomics results [17]. For
prognostic analyses, patients aged ≥75 years were excluded
because their prognosis was poor irrespective of the genetic
background, leaving 863 patients. A final set of 784 patients
with a complete dataset comprising variant and CN calls,
survival data and ISS had a median follow-up of
22.9 months (range 0.0–52.9), median PFS of 31.2 months
(range 0.0–51.6), and median OS not reached, Supple-
mentary Table 1. Of note, lactate dehydrogenase (LDH)
values were not universally available, preventing the cal-
culation of R-ISS for all patients, hence, the IMWG risk
criteria were used [13]. The final analysis subset (n= 784)
compares similarly to the full dataset (n= 1273) for major
clinical features other than age due to the exclusion of
patients ≥75 years, Supplementary Table 1. DNA-driver
status was assigned based on previously established criteria,
as outlined in the accompanying genomic results [17–19].
The study had 95% power to identify the significantly
mutated genes occurring at the 5% level, accompanying
genomic results [17].
Detailed statistical methods are available in the Supple-
mentary Methods. The Kaplan–Meier estimator was used to
calculate time-to-event distributions. Stepwise Cox regres-
sion was used to select variables and estimate the effects of
Fig. 1 Study outline. Data from 784 patients were used to identify
univariate and multivariate features associated with PFS. Genetic
features were used for multivariate modeling and were also used in a
recursive partitioning model with significantly different outcomes
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significant covariates for time-to-event outcomes. Cumula-
tive R2, the percentage of variance explained by a factor or
set of factors, was calculated [20] for the factors entering
regression models based on the order in which they were
entered into the models. Recursive partitioning was used to
classify patients into risk strata. Genetic factors significantly
associated with PFS in the multivariate Cox model were
considered first, followed by the addition of age and ISS in
the presence of these adverse genetic factors.
Results
Genetic contributors to outcome
The study outline is shown in Fig. 1. A summary of baseline
clinical and molecular features is provided, Supplementary
Table 1. The dataset used to establish the risk models has
27% ISS Stage III patients, comparable to several recent
studies [7, 21]. A key distinction between this population (n
= 784) and other datasets is that patients ≥75 years were
removed (Supplementary Figure 3). The study group com-
prised 45% of patients aged 65–74 years, a greater per-
centage than other similar studies [14]. The impacts of
cytogenetic variables, immunoglobulin heavy chain gene
(IGH) translocations, and hyperdiploidy on outcome are
provided in Supplementary Figure 4. The presence of IGH
translocations including t(4;14) was significantly associated
with worse PFS but not OS, while hyperdiploidy was not
associated with outcome.
Structural rearrangements, SNV mutations, and CN
abnormalities were called to identify key MM driver genes
[17]. To determine if these variables contribute to the risk
status, we plotted them against currently used markers of
risk, including ISS, IMWG, and time to relapse (Fig. 2).
The distribution of genetic features was not dependent upon
IMWG risk group, except for t(4;14) and del17p, which are
part of the definition of risk (Fig. 2a), or ISS (Fig. 2b). This
indicates that clinical and genetic features are not strongly
associated, and clinical prognostic models may benefit from
the inclusion of genetic factors. The distribution of genetic
features by time to relapse (Fig. 2c), and the percentage
breakdown of timing of relapse within each genetic feature
is shown in Fig. 2d. The key differences in the percentage of
patients with early relapse defined by genetic markers
provide a rationale for building the models to predict the
poor outcome, featuring genetic markers as covariates.
Univariate Cox regression
To determine the markers which contribute to high-risk
disease, we analyzed 784 patients with complete ISS, PFS,
OS, and genomic data. The results of univariate analyses for
PFS and OS for molecular features are shown, Supple-
mentary Tables 2–5. All features significantly associated
with either PFS or OS in a univariate model are presented in
Fig. 3a, b and Supplementary Tables 7 and 8. For PFS, a
protective effect was associated with ISS I, mutation of
TRAF3, and gain/amplification of 7q, 15q, and 19q. An
adverse association was seen for ISS II/III, age ≥ 65 years, t
(4;14), mutation of TGDS, gain or amplification of CKS1B
or MYC, loss of FAM46C, and mono-allelic or bi-allelic
inactivation of RB1, TRAF2, or TP53. Additionally, the
level of global loss of heterozygosity (LOH) > 4.6% and CN
clusters associated with 1q gain/amp (described in asso-
ciated genomics results) [17] were associated with poor PFS
(Supplementary Methods). Similarly for OS (Fig. 3b), ISS
stage I and mutation of TRAF3 were associated with a
positive effect, whereas an adverse association was seen
with ISS stage II/III, age ≥ 65 years, the APOBEC signature,
global LOH > 4.6%, mutation TGDS, gain or amplification
of CKS1B, loss of FAM46C, RPL5, FGFR3, or PARK2, and
mono-allelic or bi-allelic inactivation of CDNK2C and
TP53. Although loss or mutation of TP53 was significantly
associated with shorter OS, the effect was strongest with bi-
allelic inactivation. The opposite was seen with FAM46C,
where loss was significant for the outcome, but mutation
was not (Supplementary Figure 5). The combined effect of
bi-allelic loss of FAM46C was not significant, whereas loss
alone was, Supplementary Tables 2 and 4.
Interactions between molecular variables were tested,
Supplementary Table 6. For PFS, a significant interaction
was observed univariately between t(4;14) and bi-allelic
TP53 (P= 0.0217), and between ZNF426 (chr. 19) gain and
FAM46C loss (P= 0.0202), while the interaction between
CKS1B gain/amplification and ABCD4 (chr. 14) loss was
just above the threshold for significance (P= 0.0538). For
OS, a significant interaction was observed between CKS1B
[1q] gain/amplification and FAM46C [1p] loss (P=
0.0461), Supplementary Figure 6 and Supplementary
Table 6. In all cases, the presence of both features was
associated with poor prognosis.
Multivariate Cox regression
The approach for multivariate Cox modeling was to (1)
obtain a model by allowing entry of only genetic features,
(2) include all significant interactions after testing all pos-
sible pairs of interactions among significant genetic factors
selected by multivariate Cox regression, and finally (3)
adjust this model for age, ISS, and study site to obtain a
final composite model for outcome. The initial PFS model
for genetic markers (prior to adjustment for clinical factors)
featured: CKS1B gain/amplification (three-level variable),
bi-allelic TP53 inactivation (three-level variable), LOH >
4.6%, and t(4;14) (Fig. 3c and Supplementary Table 9).
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Pair-wise interactions between these CN and bi-allelic
inactivated covariates were tested for significance, as were
the significant and borderline-significant interactions in the
univariate setting; ultimately, only t(4;14) and bi-allelic
TP53 interactions entered into the model as significant in
multivariate analysis. After adjustment for age, ISS, and
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study site, all aforementioned genetic factors remained in
the model, but study site indicator was removed from the
final model due to non-significance.
The initial model for OS based on genetic markers (prior
to adjustment for clinical factors) featured: bi-allelic TP53
inactivation (three-level variable) and CKS1B gain/amplifi-
cation (three-level variable) (Fig. 3d and Supplementary
Table 10). Pairwise interactions between these CN and bi-
allelic covariates were tested for significance, and no sig-
nificant interactions entered into the model. After adjust-
ment for age, ISS, and study site, all previously mentioned
genetic factors remained in the model, and the study site
indicator was removed from the final model due to non-
significance.
For both PFS and OS models, interactions between all
mutational, CN, and bi-allelic inactivation factors were
considered for inclusion in multivariate models both before
and after adjustment for clinical effects. The final model of
PFS has a cumulative R2 of 34.3% and the set of genetic
factors included in the model without adjustment for age
and ISS has a cumulative R2 of 18.4%. The final model of
OS has a cumulative R2 of 46.5% and the set of genetic
factors included in this model without adjustment for age
and ISS have a cumulative R2 of 25.2%. A visualization of
Fig. 2 The association of myeloma-acquired genetic variants with
clinical risk groups. a The distribution of driver mutations, translo-
cations, and copy number alterations by IMWG risk status. It can be
seen that a limited number of variables explain a proportion of risk, as
would be anticipated based on how the IMWG risk status is assessed,
but it can be seen clearly that these variants do not explain a significant
amount of variability in clinical outcome. b The distribution of driver
mutations, translocations, and copy number alterations by ISS. The
distribution shows the independence of ISS from the genetic data,
suggesting that a patient’s ISS stage cannot be predicted by mutational
diagnosis (and vice-versa); also, that using both could be important for
modeling patient outcomes. c Bar plot shows the contribution of each
driver variant to relapse, with a breakdown of PFS over <6 months/
6–12 months/12–18 months/>18 months, or no progression. Patients
with censored follow-up <18 months were excluded from the analysis.
d The same data as in plot (c) was only expressed as a proportion, with
features sorted by the proportion, of patients who relapsed within the
first year of therapy. Differences in rates in early relapse across genetic
features suggest a motivation for the inclusion of such features in
predictive modeling for poor patient outcome
Fig. 3 Molecular and clinical features associated with outcome. Sig-
nificant associations of genetic and clinical factors with PFS (a) and
OS (b) in univariate analyses. Covariates investigated include, age,
ISS, IGH translocations, MYC translocation, APOBEC signature,
hyperdiploidy, LOH%, homologous recombination deficiency muta-
tions, copy number cluster, mutational data, copy number data, and bi-
allelic inactivation data. Covariates significantly associated with at
least one of PFS or OS (Wald P ≤ 0.05) in univariate models are
presented. c The final multivariate model for PFS containing clinical
and genetic factors has a cumulative R-squared of 34.3% compared to
a cumulative R-squared of 18.4% for the model developed containing
only genetic factors. d The final model for OS contains clinical and
genetic factors, and has a cumulative R-squared of 46.5% compared to
a cumulative R-squared of 25.2% for the model developed containing
only genetic factors
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Fig. 4 A recursive partitioning model for PFS and OS identified
clinical and genomic markers associated with risk. a A recursive
partitioning model for PFS based on the inclusion of genetic and
clinical predictors, showing the terminal nodes. b Kaplan–Meier
curves were generated for PFS for all terminal nodes of the tree. c
Nodes with similar outcome profiles were combined to generate three
risk groups. Nodes 8 and 18 were combined to designate low-risk
patients (green); nodes 11, 19, and 6 were combined to designate
intermediate-risk patients (red); nodes 10 and 7 were combined to
designate Double-Hit patients (blue). Double-Hit comprised 6.1% of
the total patient population and included patients who were either of
the following: bi-allelic inactivation of TP53 or ISS stage III with
amplification of CKS1B. Significant differences in PFS between the
risk groups are identified (P < 0.0001). d As in (c) with OS. e The risk
groups identified in (c) were applied to a subset of Total Therapy
patients (n= 85) with available genetic data; significantly different
PFS outcomes are observed, with especially poor PFS in Double-Hit
patients (P < 0.0001). f As in (e) with OS
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the contribution of individual factors in the final models of
PFS and OS to the total R2 is given (Fig. 3).
Recursive partitioning to identify high-risk Double-
Hit cases
To identify patients at high risk of early progression,
recursive partitioning was performed using the genetic and
clinical factors identified in the final multivariate Cox model
for PFS. In an initial analysis using only molecular features
the first three splits of the tree identified TP53 bi-allelic
inactivation and amplification of CKS1B corresponding to
nodes 2 and 7 (Supplementary Figure 7A). For both nodes,
the log-rank P-value for PFS when compared to the node
featuring patients with none of these features (node 6) was
less than 0.05, indicating that poor PFS is associated with
each of these genetic features (Supplementary Figure 7B).
Based on this, TP53 bi-allelic inactivation and amplification
of CKS1B were considered adverse genetic features, and
indicators were created for all patients for the presence of at
least one or both of these factors. Of the 80 patients with at
least one of the two adverse genetic factors, 77 patients had
exactly one, while three had both adverse factors.
Recursive partitioning was subsequently applied using
both clinical features (age, ISS) and the presence of ≥1 of
the two adverse genetic factors identified above to create the
final tree (Fig. 4a). Nodes were assessed for PFS (Fig. 4b),
and a schema for risk classification was generated by
combining the resultant seven nodes into groups with
similar PFS to generate three risk groups (Fig. 4c). Nodes 8
and 18 were grouped and considered low risk (49.4%),
containing patients who were younger, had lower disease
stage (ISS I or II), and no genetic factors. The intermediate-
risk group (44.5%, nodes 11, 6, and 19) was a mixture of
patients with either older age (node 19), higher disease stage
without genetic factors (node 6), or who were lower stage
with wild-type TP53, but amplification of CKS1B (node 11).
These data are similar to the IMWG consensus on risk
stratification where low-risk patients had low/intermediate
disease stage and no genetic factors, and intermediate-risk
was defined by either (a) ISS I plus t(4;14) or del17p, or (b)
ISS III with no genetic factors [13].
Nodes 7 and 10 were grouped to generate a subset of
high-risk patients referred to as Double-Hit, who had the
poorest prognosis (median PFS 15.4 months, median OS
20.7 months). This group comprises 6.1% of patients and is
defined by bi-allelic inactivation of TP53 or ISS III with
amplification of CKS1B. Significant overall differences in
PFS and OS (P < 0.0001) were observed between these
groups (Fig. 4c, d). For the Double-Hit group (n= 48), 27
patients (56.3%) were ISS III, 24 (50%) were ≥65 years, 30
(62.5%) had bi-allelic inactivation of TP53, and 21 (43.8%)
had amplification of CKS1B. The adverse impact of these
genetic features on outcomes can be appreciated when these
cases are compared to patients in node 6 (ISS III, no genetic
factors). The median PFS of Double-Hit patients was
9 months shorter than those in node 6 (15.4 vs.
24.4 months, respectively P < 0.01) and the median OS was
20.7 months vs. not reached (P < 0.01) (Fig. 4b).
Validation of approach on an independent dataset
To understand how the Double-Hit subgroup performed in
an independent dataset, we analyzed NDMM patients with
longer follow-up derived from Total Therapy (TT) trials. A
total of 85 patients (median PFS 6.25 years, median OS not
reached) (Supplementary Methods, Supplementary Table 1)
[22] had available clinical-sequencing and targeted-
sequencing panel data, and could be segmented based on
the recursive partitioning model (Fig. 4). This analysis
Fig. 5 Comparison of IMWG and Double-Hit cases. a Patients were
classified by IMWG status and recursive partitioning risk groups, as
detailed in Fig. 4. Double-Hit patients have very poor PFS, whether
classified as high risk by IMWG (median PFS 11-month, 18-month
PFS of 35%) or low/intermediate risk by IMWG (median PFS 16-
month, 18-month PFS of 44%). b Similar trends were observed for OS
classified by both IMWG and recursive partitioning status
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identified a Double-Hit group of similar size and outcome,
(9.4% [8/85], median PFS 11.6 months, median OS
27.2 months) (Fig. 4e, f). These results demonstrate the
effectiveness of the classification of Double-Hit MM
patients on an external validation set.
Comparison to the IMWG risk classifier
A comparison of Double-Hit identified by recursive parti-
tioning to the established IMWG classifier provides an
opportunity to contextualize the adverse outcome associated
with Double-Hit patients [13]. The distribution of patients
by IMWG risk group and recursive partitioning is provided
(Supplementary Tables 1 and 11). Patients classified as
Double-Hit by the recursive partitioning model had poor
outcome, whether classified as high risk by IMWG criteria
(n= 24; 18-month estimates PFS: 35%, OS: 37%) or low/
standard risk (n= 24; PFS: 44%, OS: 73%). Additionally,
patients classified as high risk by IMWG criteria, but clas-
sified as low risk (n= 30; PFS: 69%, OS: 88%) by recursive
partitioning or intermediate risk (n= 53; PFS: 74%, OS:
94%) had similar outcome to patients classified as low/
standard risk by IMWG, but intermediate risk by recursive
partitioning (n= 296; PFS:67%, OS:85%) (Fig. 5).
Molecular markers of Double-Hit MM
In the full dataset, TP53 deletion was seen in 9.0% (97/
1074) and mutations in 5.5% (70/1273) of patients. Any
event at TP53 was found in 11.3% and bi-allelic events in
3.7% of patients. Mutations were predominantly found in
the DNA-binding domain (80.2%, 65/81), with 7.4% (6/81)
in the oligomerization domain (Fig. 6a). There were recur-
rent mutations in 17 codons comprising 48.1% (39/81) of
mutations, with R248 (n= 4), R175, G199, and Y234 (all n
= 3) being the most frequent. Missense mutations in TP53
were seen in 77.8% (63/81), with the remaining 22.2% (18/
81) being potentially protein-terminating comprising fra-
meshift, splice site, or nonsense mutations.
Bi-allelic inactivation of TP53 is the crucial driver of
prognosis, P < 0.0001, when compared to wild-type or
mono-allelic inactivation for both PFS and OS. Importantly,
when mutations of TP53 are taken into account, CN loss of
17p, a feature previously used to identify adverse risk [13],
is not prognostically important (Fig. 6b, c). Interestingly,
other studies reported similar PFS and OS in patients with
bi-allelic inactivation of TP53, but unlike our analysis, none
provided a comprehensive or compelling reason to include
these features into the definition of high risk [23, 24].
Fig. 6 The sites of TP53 mutation and their Impact on survival. a
Schematic of mutations detected in TP53. b Kaplan–Meier survival
curve for PFS for complete set (n= 863) of NDMM patients <75 years
of age who had SNV and CNV results, and survival data by TP53 bi-
allelic, mono-allelic, or wild-type status. Note that this dataset is larger
than the n= 784 dataset, since for this analysis, presence of ISS was
not required. c OS in the same set of patients (n= 863)
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The second genomic variable that defines the Double-Hit
group is amplification (≥4 copies) of CKS1B in the context
of ISS III. In contrast to the gain of CKS1B (21.9%, 189/
863), the group with amplification constitutes a much
smaller subset (6.3%, 54/863). In the complete dataset (n=
863), both gain and amplification of CKS1B were associated
with decreased PFS and OS, but the effect was more pro-
nounced in patients with amplification (18-month estimates,
gain vs. amplification; PFS: 71 vs. 60% (P= 0.06; OS: 88
vs. 73%, P= 0.08) (Fig. 7). Other than its occurrence in a
clinical group defined by ISS III, we could not identify
additional adverse PFS when amp1q occurred with del17p,
bi-allelic TP53, t(4;14), or t(14;16) (Supplementary
Table 6). Interestingly, amplification of CKS1B did not
appear to affect OS ≤ 12 months, but there was clear
separation after this time, suggesting that it may have a
greater effect on the intermediate group after more pro-
longed follow-up (Fig. 7c).
Discussion
Using comprehensive, genome-wide analysis, we identified
Double-Hit myeloma, a new, genomically defined high-risk
group of patients with extremely poor outcome, despite
treatment with novel therapies (18-month estimates of PFS
and OS are 39% and 48%, respectively). Among 34
Double-Hit patients with available treatment data, 85% (29/
34) received a ≥three-drug induction regimen with 44% (15/
34) of these being a triplet (combinations of bortezomib,
dexamethasone, cyclophosphamide, and lenalidomide most
commonly). Compared to IMWG criteria traditionally used
in the clinic, outcomes for Double-Hit patients are similar
whether the patients are IMWG high risk (18-month esti-
mates of PFS and OS are 35% and 37%, respectively) or
IMWG low/standard risk (18-month estimates of PFS and
OS are 44% and 73%, respectively). The similarly poor
outcomes of these two groups, especially when compared to
other possible classifications by IMWG risk and recursive
partitioning, suggests that existing classifiers of high risk
fail to identify some of the patients at greatest risk for poor
clinical outcome and that defining Double-Hit constitutes a
significant step forward. Given the frequency of gain and
amplification of 1q (21.9% and 6.1%, respectively in this
study) and the impact on the outcome, either addition of
these features, or revision to classify them as part of the
high-risk definition in the R-ISS and IMWG risk stratifi-
cation methods could improve the current risk criteria [13,
14]. It seems that making the distinction between gain and
amp1q is the key to identifying a high-risk group of
patients, and that in future studies, a clear distinction
between the two states should be discerned.
Importantly, the number of prognostic molecular features
required to identify the Double-Hit group is small, making
their inclusion into clinically valuable risk stratification
approaches relatively simple. There are only two highly
penetrant genetic features which define the Double-Hit
status. However, the molecular criteria rely on discerning
subtle differences in TP53 (bi-allelic vs. deletion) and 1q
(amp vs. gain), so it is important that diagnostic tests can
easily discriminate between them. The ease and speed of
detection of DNA markers are key features that are relevant
in the clinic, and the limited number of variables required
for identification of Double-Hit patients is an advantage. It
is important to not just determine the CN status of 17p, but
also determine the mutational status of TP53. In addition,
fluorescence in situ hybridization (FISH) probes may not be
sensitive enough to identify small deletions in TP53, such
as exonic or promoter deletions, resulting in misclassifica-
tion of patients. As such, modern molecular tests should be
Fig. 7 The association of gain and amplification of 1q21 with survival
using CKS1B as the marker. a Kaplan–Meier survival curves for PFS
based on either gain or amplification (≥4 copies) of CKS1B (1q21).
The data are shown for the complete dataset (n= 863) of NDMM
patients who were <75 years of age who had SNV and CNV results
and survival data. Note that this dataset is larger than the n= 784
dataset, since for this analysis, the presence of ISS was not required. b
OS in the same set of patients (n= 863)
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used, such as sequencing panels to accurately determine
TP53 status. These need not be myeloma-specific panels, as
many vendors provide kits or services for TP53 [25, 26].
NGS-based assays can detect TP53 mutation/deletion and
gain/amplification of 1q when present in >30% of cells,
allowing efficient detection of prognostically important
variants at levels comparable to interphase FISH. NGS-
based definition of these abnormalities will also generate a
more homogenously defined population by removing
variability generated by cytogenetic frequency calls,
allowing more reproducibility.
Using the largest dataset available, we show that bi-allelic
alteration of TP53 is present in 3.7% of NDMM and is
associated with very poor outcome. Bi-allelic inactivation of
TP53 has been reported higher at relapse, having been
reported at 21–26% [27–29], and is also observed in other
hematological malignancies, including chronic lymphoctic
leukemia (CLL) and acute lymphoblastic leukemia (ALL)
[30, 31]. In all, TP53 mutations are reported at 15.7% and,
like myeloma, patients with bi-allelic inactivation have shorter
OS compared to either mutation or deletion alone [31].
In NDMM, we show that deletion of 17p alone is not
prognostic; in fact when mutation in TP53 is accounted for,
monosomy 17p alone has no prognostic value. The prog-
nostic relevance of this highlights the need for sequencing
of TP53 in diagnostic laboratories. Previous studies detec-
ted TP53 mutations in 3–8% of myeloma patients, varying
by dataset size and technique used [15, 16, 32]. We show
that mutation of TP53 is present in 5.5% of patients. Similar
to other cancers [33, 34], mutations in TP53 are pre-
dominantly missense mutations in the DNA-binding
domain. Nonsense or frameshift mutations were relatively
rare, given that TP53 is a tumor suppressor gene, and the
predominance of missense mutations may indicate altered
function of TP53 rather than complete inactivation.
CN gains of 1q have long been associated with poor
outcome, and it is known that as the number of copies of 1q
increases, there is an association with worse outcome [35,
36]. Definitions of amp1q vary throughout the literature,
making it difficult to determine the true prognostic impact
of gain vs. amplification. We used ≥4 copies to define
amp1q and show an association with significantly poorer
outcome, especially on a background of ISS III. The bio-
logical meaning of amp1q is difficult to determine; some
studies have suggested overexpression of specific particular
genes that are overexpressed on 1q, or mechanisms of
genome instability that cause the amplification through
translocations and hypomethlation [5, 36–39].
The possibility remains that additional prognostically
important genomic features contributing to early relapse
could be identified in future; however, we believe that this is
unlikely, given the size of this dataset. Also, this analysis
focused on DNA-based features; however, an integrated
analysis that includes whole-transcriptome data is ongoing.
Despite its size, the study currently lacks the power to
exclude subtle contributions of genetic variables to long-
term survival because of limited follow-up; however, this
was not the purpose of the analysis. Instead, we investigated
whether patients with extremely poor outcome at pre-
sentation could be identified using molecular features where
experimental therapeutic strategies could be explored.
An important future direction will be discussion and
engagement with myeloma working groups and integration
of these data into consensus risk stratification criteria to
ensure communication and adoption throughout the global
myeloma community. In addition, engagement with reg-
ulatory agencies will be needed to explore inclusion of the
Double-Hit group in clinical studies. These patients can be
readily identified using NGS-based assays, providing an
opportunity to evaluate innovative therapeutic strategies,
such as chimeric antigen receptor T cells, to address their
unmet medical need.
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